INCY has been the topic of a number of other reports. Credit Suisse Group assumed coverage on shares of Incyte in a research note on Monday, May 20th. They set a “neutral” rating and a $75.00 target price on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte in a research note on Tuesday, April 30th. Oppenheimer set a $85.00 target price on shares of Incyte and gave the stock a “hold” rating in a research note on Sunday, April 7th. Gabelli raised shares of Incyte from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a research note on Wednesday, January 23rd. Finally, Zacks Investment Research cut shares of Incyte from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 23rd. Thirteen analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $88.00.
Shares of NASDAQ INCY traded up $1.34 during trading on Wednesday, hitting $77.71. The company had a trading volume of 1,250,400 shares, compared to its average volume of 1,407,600. Incyte has a fifty-two week low of $57.00 and a fifty-two week high of $88.83. The firm has a market cap of $16.38 billion, a price-to-earnings ratio of 94.77 and a beta of 1.20. The company has a quick ratio of 5.21, a current ratio of 5.22 and a debt-to-equity ratio of 0.01.
In other Incyte news, EVP Paula J. Swain sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $87.01, for a total transaction of $870,100.00. Following the completion of the transaction, the executive vice president now owns 38,295 shares in the company, valued at approximately $3,332,047.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 17.10% of the company’s stock.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc lifted its position in shares of Incyte by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 18,380,804 shares of the biopharmaceutical company’s stock worth $1,269,746,000 after buying an additional 120,700 shares during the last quarter. BlackRock Inc. raised its position in Incyte by 1.2% in the 1st quarter. BlackRock Inc. now owns 15,453,453 shares of the biopharmaceutical company’s stock valued at $1,329,154,000 after purchasing an additional 190,491 shares during the last quarter. Norges Bank purchased a new stake in Incyte in the 4th quarter valued at $186,630,000. Geode Capital Management LLC raised its position in Incyte by 6.2% in the 1st quarter. Geode Capital Management LLC now owns 2,508,013 shares of the biopharmaceutical company’s stock valued at $215,338,000 after purchasing an additional 147,407 shares during the last quarter. Finally, Northern Trust Corp raised its position in Incyte by 2.1% in the 1st quarter. Northern Trust Corp now owns 2,014,831 shares of the biopharmaceutical company’s stock valued at $173,296,000 after purchasing an additional 41,396 shares during the last quarter. Institutional investors and hedge funds own 91.17% of the company’s stock.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.